- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MERUS LABS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MPH HEALTH CARE | 19,800 | +1,02 % | Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH): Kaufen | Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH
21.11.2025 / 12:01 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| EYEPOINT | 12,200 | -3,94 % | EyePoint, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| AMARIN | 12,500 | +1,63 % | Amarin Corporation plc: Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA/VAZKEPA (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization | DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 4,280 | -3,82 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 22,200 | -0,89 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3%... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 435,50 | -3,63 % | Madrigal Pharmaceuticals-Aktie +12%: Kommt's zur Übernahme? | Die Aktie des US-Pharmaunternehmens Madrigal Pharmaceuticals hat einen kräftigen Kurssprung verzeichnet, nachdem Spekulationen über eine mögliche Übernahme durch den Pharmariesen Eli Lilly aufkamen.... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 68,00 | -0,73 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules | PRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets | Northvale, New Jersey--(Newsfile Corp. - April 2, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| DOGECOIN CASH | - | - | Dogecoin Cash, Inc. (OTCQB: DOGP) Announces Development Initiative for "Dogecoin Gold" Digital Asset Framework | MESQUITE, NV, April 17, 2026 (GLOBE NEWSWIRE) -- Dogecoin Cash, Inc. (OTCQB: DOGP) ("DOGP" or the "Company") today announced it is advancing the development of "Dogecoin Gold," a proposed blockchain-based... ► Artikel lesen | |
| BLUM HOLDINGS | - | - | BLUM HOLDINGS, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | ||
| THERIVA BIOLOGICS | 0,254 | +0,99 % | Theriva Biologics, Inc.: Theriva Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting | - Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 11,060 | +1,28 % | Kazia Therapeutics Limited: Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform | SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with... ► Artikel lesen | |
| ALLERGY THERAPEUTICS | 0,112 | 0,00 % | Allergy Therapeutics - Interim Results for six months ended 31 Dec 2025 | ||
| ACURA PHARMACEUTICALS | - | - | ACURA PHARMACEUTICALS, INC - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | ||
| BIOSTAR PHARMACEUTICALS | - | - | Biostar Pharma, Inc.: Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases | SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. wholly-owned subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Stock Cod e: 2563.HK)... ► Artikel lesen |
Das Unternehmen MERUS LABS INTERNATIONAL INC kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MERUS LABS INTERNATIONAL INC finden Sie auf Wallstreet Online.